Table Info

Table 1.

HCV RNA+ patients on SOWL before and after introduction of DAAs

Indicator	Measure	Overall 2008–2019	P1, Years 2008–2013	P2, Years 2014–2019	Difference P2 – P1	Mann-Whitney U test Monte-Carlo-Significance (2-sided)
A) Listed on SOWL by requested organ
Any organ	Sum	328	229	99	–130	P = 0.004 (99% CI = 0.002 to 0.006)
	Mean	27.33	38.17	16.5	–21.67
	SD	13.51	8.21	7.23
Liver	Sum	284	197	87	–110	P = 0.004 (99% CI = 0.002 to 0.005)
	Mean	23.67	32.83	14.5	–18.33
	SD	11.56	7.65	5.82
Kidney	Sum	38	28	10	–18	P = 0.031 (99% CI = 0.027 to 0.036)
	Mean	3.17	4.67	1.67	–3
	SD	2.38	1.86	1.86
B) Delisted from SOWL by reason
Transplanted	Sum	215	141	74	–67	P = 0.010 (99% CI = 0.007 to 0.012)
	Mean	17.92	23.5	12.33	–11.17
	SD	7.68	4.42	5.96
Not transplanted	Sum	28	21	7	–14	P = 0.049 (99% CI = 0.043 to 0.054)
	Mean	4.67	3.5	1.17	–2.33
	SD	2.27	2.43	1.47
Deceased	Sum	42	33	9	–24	P < 0.001 (99% CI = 0 to 0.0005)
	Mean	3.5	5.5	1.5	–4
	SD	2.54	1.76	1.22

CI: confidence interval

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100532_sup_1.pdf.

Declaration

Author contributions

LF: Methodology, Formal analysis, Visualization, Validation, Writing—original draft. ST: Investigation, Conceptualization, Data curation, Writing—original draft. PB: Investigation, Supervision, Funding acquisition, Supervision, Resources, Project administration, Validation, Writing—original draft, Writing—review & editing. FI: Conceptualization, Supervision, Resources, Funding acquisition, Project administration, Supervision, Validation, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This retrospective study was performed on anonymous, non-personal data. An assessment by an ethics committee was therefore unnecessary, according to the Swiss ethics regulations.

Consent to participate

This study is in accordance with the Swiss federal law on research involving human subjects (Human Research Act, HRA), which allows the working of anonymized aggregated health related personal data without consent to participate.

Consent to publication

Not applicable.

Availability of data and materials

Data and materials is available at the corresponding author upon request.

Funding

Not applicable.

Copyright

References

Bihl F, Bruggmann P, Castro Batänjer E, Dufour JF, Lavanchy D, Müllhaupt B, et al. HCV disease burden and population segments in Switzerland. Liver Int. 2022;42:330–9. [DOI] [PubMed] [PMC]

The Swiss hepatitis strategy [Internet]. Zurich: The Swiss hepatitis strategy; c2019 [cited 2019 Jun 1]. Available from: https://en.hepatitis-schweiz.ch/projects-and-campaigns/swiss-hepatitis-strategy

Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030 [Internet]. Switzerland: World Health Organisation; c2022 [cited 2022 Jul 18]. Available from: https://www.who.int/publications/i/item/9789240053779 [DOI] [PubMed]

Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58–68. [DOI] [PubMed]

Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, et al.; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25:152–60. [DOI] [PubMed]

Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol. 2015;7:78–92. [DOI] [PubMed] [PMC]

Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–60. [DOI] [PubMed]

Kesiraju S, Srikanti P, Sahariah S. Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. Virusdisease. 2017;28:233–41. [DOI] [PubMed] [PMC]

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637–48. [DOI] [PubMed] [PMC]

10.

Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39–52. [DOI] [PubMed] [PMC]

11.

Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13:2249. [DOI] [PubMed] [PMC]

12.

Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern Med. 2023;183:97–105. [DOI] [PubMed] [PMC]

13.

An J, Park DA, Ko MJ, Ahn SB, Yoo JJ, Jun DW, et al. Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis. J Pers Med. 2022;12:1517. [DOI] [PubMed] [PMC]

14.

SOAS: Organzuteilung nach den Regeln des gesetzes [Internet]. Berne; c2020 [cited 2020 Jul 23]. Available from: https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/transplantationsmedizin/transplantieren-von-organen-geweben-Zellen/zuteilung-organe-gewebe-blut-stammzellen/soas.html

15.

Temperli S. Hepatitis C in Organspende und Organtransplantation in der Schweiz eine Datenanalyse [Dissertation]. Bern: University of Bern; 2022.

16.

Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology. 2022;76:139–54. [DOI] [PubMed] [PMC]

17.

Latt NL. Update on the management of hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. Gastroenterol Hepatol (N Y). 2018;14:687–705. [PubMed] [PMC]

18.

Arias ABV, Villegas Herrera MT, Arco Sánchez A, Adel ME, Triguero Cabrera J, Plata Illescas C, et al. Indication for liver transplantation after direct-acting agents in the treatment of patients with hepatitis C. Transplant Proc. 2022;54:32–4. [DOI] [PubMed]

19.

Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, et al.; all the contributing centers (www. eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. an ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–7. [DOI] [PubMed]

20.

Brancaccio G, Vitale A, Signoriello G, Gaeta GB, Cillo U. Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infect Dis (Lond). 2020;52:557–62. [DOI] [PubMed]

21.

Parrish NF, Feurer ID, Matsuoka LK, Rega SA, Perri R, Alexopoulos SP. The changing face of liver transplantation in the United States: the effect of HCV antiviral eras on transplantation trends and outcomes. Transplant Direct. 2019;5:e427. [DOI] [PubMed] [PMC]

22.

Young K, Liu B, Bhuket T, Gish RG, Wong RJ. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. J Viral Hepat. 2019;26:350–61. [DOI] [PubMed]

23.

Brunner N, Bruggmann P. Trends of the global hepatitis C disease burden: strategies to achieve elimination. J Prev Med Public Health. 2021;54:251–8. [DOI] [PubMed] [PMC]

24.

Blach S, Razavi-Shaerer D, Mooneyhan E, Estes C, Razavi-Shaerer K, Gamkrelidze I, et al. Updated evaluation of global progress towards HBV and HCV elimination, preliminary data through 2021 (not good). The Liver Meeting Digital Experience AASLD; The Liver Meeting Washington, DC; November 4-8, 2022; Washington; 2022 Nov. 4–8; Washington; 2022.

25.

Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, et al. Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting hepatitis C virus therapy in Germany? J Clin Gastroenterol. 2020;54:192–9. [DOI] [PubMed]